Holen Sie sich die Stockscreener-App
17.35
3.34%
0.56
Handel nachbörslich:
17.39
0.04
+0.23%
Schlusskurs vom Vortag:
$16.79
Offen:
$17.05
24-Stunden-Volumen:
376.59K
Relative Volume:
1.55
Marktkapitalisierung:
$455.09M
Einnahmen:
$31.38M
Nettoeinkommen (Verlust:
$-6.69M
KGV:
-66.73
EPS:
-0.26
Netto-Cashflow:
$-1.84M
1W Leistung:
+2.24%
1M Leistung:
+39.36%
6M Leistung:
+89.20%
1J Leistung:
+405.83%
1-Tages-Spanne:
$16.43
$17.55
1-Wochen-Bereich:
$16.43
$17.74
52-Wochen-Spanne:
$3.18
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Firmenname
Eton Pharmaceuticals Inc
Sektor
Telefon
(847) 787-7361
Adresse
21925 W. FIELD PARKWAY, DEER PARK, IL
Vergleichen Sie ETON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
17.35 | 455.09M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
161.92 | 70.37B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.19 | 48.41B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
10.71 | 47.91B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.96 | 18.80B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
310.80 | 13.47B | 2.76B | 1.11B | 898.10M | 22.77 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-23 | Bestätigt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-01-06 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-05-06 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-01-04 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-20 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten
A Look Ahead: Eton Pharmaceuticals's Earnings Forecast - Nasdaq
Eton Pharmaceuticals Inc expected to post earnings of 5 cents a shareEarnings Preview - TradingView
Envestnet Asset Management Inc. Invests $236,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Barclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33% - simplywall.st
Eton Pharmaceuticals Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 - The Manila Times
Eton Pharmaceuticals to Report Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Rare Disease Leader Eton Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Coming May 13 - Stock Titan
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release - Yahoo Finance
Q1 EPS Estimate for Eton Pharmaceuticals Boosted by Analyst - Defense World
JPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
B. Riley Raises Earnings Estimates for Eton Pharmaceuticals - Defense World
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
Eton Pharmaceuticals (ETON) Submits NDA for New Treatment for Ce - GuruFocus
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment (ETON:NASDAQ) - Seeking Alpha
Eton Pharmaceuticals Submits NDA to FDA for ET-600 to Treat Central Diabetes Insipidus - marketscreener.com
Eton Pharmaceuticals Says FDA Review Expected To Take 10 Months, Potential Q1 2026 Launch - marketscreener.com
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - GlobeNewswire
Groundbreaking Pediatric Diabetes Drug Advances: First-Ever Liquid Formulation Heads to FDA Review - Stock Titan
Geode Capital Management LLC Sells 4,050 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Large Increase in Short Interest - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Has Found A Path To Profitability - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Retail investors who have a significant stake must be disappointed along with institutions after Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) market cap dropped by US$35m - simplywall.st
(ETON) Technical Data - news.stocktradersdaily.com
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN
Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals - MarketScreener
Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq
Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks
Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener
Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com
Eton Pharmaceuticals licenses Increlex rights abroad By Investing.com - Investing.com UK
Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire
Major Pharma Deal: Eton's Smart Move Unlocks Global Market for Rare Disease Treatment - Stock Titan
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency… - Informazione.it
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener
Finanzdaten der Eton Pharmaceuticals Inc-Aktie (ETON)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.78%
2.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):